{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:51:59Z","timestamp":1785163919758,"version":"3.55.0"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Atherosclerotic cardiovascular disease (ASCVD) risk stratification has predominantly relied on conventional risk factors such as hypertension, hyperlipidemia, diabetes mellitus, smoking, and family history of premature ASCVD. These features, while important, often fail to capture the complex interplay of contributors to ASCVD. Inflammation is involved in the initiation, progression, and destabilization of atherosclerotic plaques. However, it has not been consistently included in cardiovascular risk stratification tools which are crucial to trigger interventions and prevent events. Thus, there has been a growing interest in incorporating inflammatory biomarkers into ASCVD risk assessment. Two researchers entered the search terms: \u201ccardiovascular\u201d AND \u201crisk stratification\u201d AND \u201cinflammation\u201d AND alternately the following aditional terms: \u201cprimary prevention\u201d OR \u201csecondary prevention\u201d OR \u201cresidual risk\u201d OR \u201cinflammatory disease\u201d in the PubMed and Open Evidence platforms. In total, 25 studies were analysed and discussed: 1 meta-analysis, 15 cohort studies, 9 cross-sectional studies. Other studies were included to support the evidence and provide context. Inflammatory-driven conditions can lead to a 24% to almost three-fold increase in cardiovascular mortality risk compared with the general population even in the absence of traditional risk factors. Furthermore, stratification of inflammatory-driven risk is largely unexplored in primary and secondary (residual risk) prevention. Traditional scores are least effective in the intermediate-risk group where a proportion of over 50% of individuals are misclassified. In secondary prevention, estimates show that 38% of individuals persist with elevated high-sensitivity C-reactive protein and these patients exhibit higher all-cause mortality, myocardial infarction and stroke rates at one year. In this review we aim to gather and appraise studies presenting alternatives to traditional risk assessment that consider the inflammatory contribution to cardiovascular events in primary and secondary prevention levels, as well as, in populations living with inflammatory-driven diseases.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1601800","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:42:23Z","timestamp":1769496143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular risk stratification in inflammatory-driven conditions: how far have we come?"],"prefix":"10.3389","volume":"13","author":[{"given":"Gustavo L. R.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei C.","family":"Sposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio","family":"Coelho-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Quinaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0254008","DOI":"10.1371\/journal.pone.0254008","article-title":"Long-term risk of death and recurrent cardiovascular events following acute coronary syndromes","volume":"16","author":"Gouda","year":"2021","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","article-title":"Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population","volume":"134","author":"Kaasenbrood","year":"2016","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-90-481-8622-8_8","article-title":"Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis","volume-title":"Cholesterol Binding and Cholesterol Transport Proteins: Structure and Function in Health and Disease","author":"Miller","year":"2010"},{"key":"B7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1161\/hc0702.104183","article-title":"Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses","volume":"105","author":"Basta","year":"2002","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(23)02878-7","article-title":"Inflammation, infection, and cardiovascular risk\u2014authors\u2019 reply","volume":"403","author":"Ridker","year":"2024","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e19658","DOI":"10.1097\/MD.0000000000019658","article-title":"Cardiovascular outcomes in patients with co-existing coronary artery disease and rheumatoid arthritis: a systematic review and meta-analysis","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1136\/annrheumdis-2020-217154","article-title":"Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease","volume":"79","author":"Logstrup","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/09612033221147471","article-title":"Cardiovascular events and risk in patients with systemic lupus erythematosus: systematic literature review and meta-analysis","volume":"32","author":"Bello","year":"2023","journal-title":"Lupus"},{"key":"B12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/rheumatology\/keab362","article-title":"All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study","volume":"61","author":"Moghaddam","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jaad.2018.12.037","article-title":"All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis","volume":"80","author":"Dhana","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.cgh.2022.08.035","article-title":"Inflammatory bowel disease is associated with an increased risk of incident acute arterial events: analysis of the United Kingdom biobank","volume":"21","author":"Alayo","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2023.02.042","article-title":"Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: a systematic review with meta-analysis","volume":"378","author":"D'Ascenzo","year":"2023","journal-title":"Int J Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/infdis\/jiab420","article-title":"Incidence of cardiometabolic diseases in people with and without human immunodeficiency virus in the United Kingdom: a population-based matched cohort study","volume":"225","author":"Gooden","year":"2022","journal-title":"J Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e70057","DOI":"10.1002\/cam4.70057","article-title":"Cardiovascular mortality in people with cancer compared to the general population: a systematic review and meta-analysis","volume":"13","author":"Ng","year":"2024","journal-title":"Cancer Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","article-title":"Cardiovascular disease risk among cancer survivors: the atherosclerosis risk in communities (ARIC) study","volume":"80","author":"Florido","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.jacc.2015.02.025","article-title":"Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all","volume":"65","author":"Navar-Boggan","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1016\/j.jacc.2016.02.055","article-title":"Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population","volume":"67","author":"Rana","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e3318","DOI":"10.1136\/bmj.e3318","article-title":"Comparisons of established risk prediction models for cardiovascular disease: systematic review","volume":"344","author":"Siontis","year":"2012","journal-title":"Br Med J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/eurheartj\/ehae048","article-title":"Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease","volume":"45","author":"Li","year":"2024","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1003498","DOI":"10.1371\/journal.pmed.1003498","article-title":"Polygenic risk scores in cardiovascular risk prediction: a cohort study and modelling analyses","volume":"18","author":"Sun","year":"2021","journal-title":"PLoS Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1093\/eurheartj\/ehy633","article-title":"Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions","volume":"39","author":"Kalkman","year":"2018","journal-title":"Eur Heart J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2021.01.012","article-title":"Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events","volume":"320","author":"Klingenberg","year":"2021","journal-title":"Atherosclerosis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1038\/s41467-020-17636-0","article-title":"Associations of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages","volume":"11","author":"Hirata","year":"2020","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-020-2121-3","article-title":"Metabolites released from apoptotic cells act as tissue messengers","volume":"580","author":"Medina","year":"2020","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1093\/eurheartj\/ehz961","article-title":"Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease","volume":"41","author":"Liberale","year":"2020","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e180066","DOI":"10.1172\/JCI180066","article-title":"Clonal hematopoiesis and atherosclerosis","volume":"134","author":"Oren","year":"2024","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s44161-023-00326-7","article-title":"Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes","volume":"2","author":"Rauch","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1161\/CIRCULATIONAHA.122.062126","article-title":"Interleukin-6 receptor polymorphism attenuates clonal hematopoiesis-mediated coronary artery disease risk among 451 180 individuals in the UK biobank","volume":"147","author":"Vlasschaert","year":"2023","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/cvr\/cvae240","article-title":"Inflammageing, a targetable pathway for preventing cardiovascular diseases","volume":"121","author":"Aranda","year":"2025","journal-title":"Cardiovasc Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.ajpc.2020.100130","article-title":"Inflammation and cardiovascular disease: from mechanisms to therapeutics","volume":"4","author":"Alfaddagh","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"c2442","DOI":"10.1136\/bmj.c2442","article-title":"An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study","volume":"340","author":"Collins","year":"2010","journal-title":"Br Med J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"933913","DOI":"10.3389\/fcvm.2022.933913","article-title":"Systemic immune-inflammation index as a potential biomarker of cardiovascular diseases: a systematic review and meta-analysis","volume":"9","author":"Ye","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/eurheartj\/ehp435","article-title":"C-reactive protein improves risk prediction in patients with acute coronary syndrome, or does it?","volume":"31","author":"Kaski","year":"2010","journal-title":"Eur Heart J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"B49","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/heartjnl-2016-310668","article-title":"Developing and validating a cardiovascular risk score for patients in the community with prior cardiovascular disease","volume":"103","author":"Poppe","year":"2017","journal-title":"Heart"},{"key":"B50","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/heartjnl-2019-315809","article-title":"Development and validation of a cardiovascular risk score for patients in the community after acute coronary syndrome","volume":"106","author":"Poppe","year":"2020","journal-title":"Heart"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1038\/sj.bjc.6601789","article-title":"Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer","volume":"90","author":"Forrest","year":"2004","journal-title":"Br J Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1038\/s41598-025-90238-2","article-title":"Association of inflammatory risk based on the Glasgow prognostic score with long-term mortality in patients with cardiovascular disease","volume":"15","author":"Zhu","year":"2025","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1161\/01.CIR.0000097109.90783.FC","article-title":"Inflammatory markers and onset of cardiovascular events: results from the health ABC study","volume":"108","author":"Cesari","year":"2003","journal-title":"Circulation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1093\/eurheartj\/ehaa160","article-title":"Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the cardiovascular inflammation reduction trial","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur Heart J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12944-024-02156-3","article-title":"The residual risk of inflammation and remnant cholesterol in acute coronary syndrome patients on statin treatment undergoing percutaneous coronary intervention","volume":"23","author":"Liao","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O'Donoghue","year":"2014","journal-title":"JAMA"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.2016.3609","article-title":"Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial","volume":"315","author":"O'Donoghue","year":"2016","journal-title":"JAMA"},{"key":"B63","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41584-023-00969-7","article-title":"Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease","volume":"19","author":"Weber","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41569-024-01045-7","article-title":"Autoimmune diseases and atherosclerotic cardiovascular disease","volume":"21","author":"Porsch","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/ijms19071890","article-title":"Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases","volume":"19","author":"Arida","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1161\/ATVBAHA.124.319983","article-title":"Immune-Mediated inflammatory diseases, dyslipidemia, and cardiovascular risk: a Complex interplay","volume":"44","author":"Wilkinson","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41584-024-01149-x","article-title":"Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases","volume":"20","author":"Buch","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.autrev.2018.01.021","article-title":"Inflammation and atherosclerosis: cardiovascular evaluation in patients with autoimmune diseases","volume":"17","author":"Escarcega","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B69","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR Recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1093\/rheumatology\/kead610","article-title":"The predictive accuracy of cardiovascular disease risk prediction tools in inflammatory arthritis and psoriasis: an observational validation study using the clinical practice research datalink","volume":"63","author":"Hughes","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3899\/jrheum.190261","article-title":"Predictive utility of cardiovascular risk prediction algorithms in inflammatory rheumatic diseases: a systematic review","volume":"47","author":"Colaco","year":"2020","journal-title":"J Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/ard.2003.018101","article-title":"Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study","volume":"63","author":"Turesson","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"B73","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","article-title":"Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis","volume":"77","author":"Crowson","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e000448","DOI":"10.1136\/lupus-2020-000448","article-title":"Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus","volume":"8","author":"Sivakumaran","year":"2021","journal-title":"Lupus Sci Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3899\/jrheum.150983","article-title":"Modified framingham risk factor score for systemic lupus erythematosus","volume":"43","author":"Urowitz","year":"2016","journal-title":"J Rheumatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e0205506","DOI":"10.1371\/journal.pone.0205506","article-title":"Performances of five risk algorithms in predicting cardiovascular events in patients with psoriatic arthritis: an Italian bicentric study","volume":"13","author":"Navarini","year":"2018","journal-title":"PLoS One"},{"key":"B77","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/cvr\/cvz058","article-title":"Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology","volume":"115","author":"Libby","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"B79","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0140-6736(22)02405-9","article-title":"Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study","volume":"401","author":"Tawfiq","year":"2023","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1093\/eurheartj\/ehaf517","article-title":"Cardiovascular biomarkers for risk stratification in primary prevention","volume":"46","author":"Neumann","year":"2025","journal-title":"Eur Heart J"},{"key":"B83","doi-asserted-by":"publisher","first-page":"ehaf658","DOI":"10.1093\/eurheartj\/ehaf658","article-title":"C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the \u2019SMuRF-less but inflamed\u2019","author":"Ridker","year":"2025","journal-title":"Eur Heart J"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"key":"B86","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","first-page":"ciae479","DOI":"10.1093\/cid\/ciae479","article-title":"Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV medicine association of the Infectious Diseases Society of America","author":"Horberg","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","article-title":"Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association","volume":"140","author":"Feinstein","year":"2019","journal-title":"Circulation"},{"key":"B90","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-016-1074-2","article-title":"The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis","volume":"18","author":"Lucke","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijcard.2016.08.129","article-title":"Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases","volume":"223","author":"Semb","year":"2016","journal-title":"Int J Cardiol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s10067-021-06002-0","article-title":"Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients","volume":"41","author":"Galarza-Delgado","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"6461","DOI":"10.3390\/jcm14186461","article-title":"Cardiovascular risk assessment in patients with rheumatoid arthritis","volume":"14","author":"Oiegar","year":"2025","journal-title":"J Clin Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"820263","DOI":"10.3389\/fmed.2022.820263","article-title":"Novel surrogate markers of cardiovascular risk in the setting of autoimmune rheumatic diseases: current data and implications for the future","volume":"9","author":"Mandel","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.4049\/jimmunol.1201719","article-title":"Neutrophil extracellular traps: double-edged swords of innate immunity","volume":"189","author":"Kaplan","year":"2012","journal-title":"J Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","article-title":"C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men","volume":"118","author":"Ridker","year":"2008","journal-title":"Circulation"},{"key":"B98","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/00033197231158937","article-title":"Assessment of systemic immune-inflammation Index and systemic inflammation-response Index in different coronary artery plaque types","volume":"74","author":"Yildiz","year":"2023","journal-title":"Angiology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12872-024-03849-4","article-title":"Systemic immune-inflammation index as a novel predictor of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention: a meta-analysis of cohort studies","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B100","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.2147\/JIR.S432506","article-title":"The systemic immune inflammatory response Index can predict the clinical prognosis of patients with initially diagnosed coronary artery disease","volume":"16","author":"Li","year":"2023","journal-title":"J Inflamm Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/MCA.0000000000001454","article-title":"Systemic immune inflammatory response index (SIIRI) in acute myocardial infarction","volume":"36","author":"Muheeb","year":"2025","journal-title":"Coron Artery Dis"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1161\/STROKEAHA.118.024305","article-title":"Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores","volume":"50","author":"Rivera-Caravaca","year":"2019","journal-title":"Stroke"},{"key":"B103","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.2147\/JIR.S384977","article-title":"Associations of inflammation with risk of cardiovascular and all-cause mortality in adults with hypertension: an inflammatory prognostic scoring system","volume":"15","author":"Cheang","year":"2022","journal-title":"J Inflamm Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.12.007","article-title":"Predicting 1-, 3- and 5-year outcomes in patients with coronary artery disease: a comparison of available risk assessment scores","volume":"318","author":"Zdanyte","year":"2021","journal-title":"Atherosclerosis"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e012433","DOI":"10.1161\/JAHA.119.012433","article-title":"Long-Term risk stratification of patients undergoing coronary angiography according to the thrombolysis in myocardial infarction risk score for secondary prevention","volume":"8","author":"Zafrir","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e008426","DOI":"10.1161\/JAHA.117.008426","article-title":"International validation of the thrombolysis in myocardial infarction (TIMI) risk score for secondary prevention in post-MI patients: a collaborative analysis of the chronic kidney disease prognosis consortium and the risk validation scientific committee","volume":"7","author":"Mok","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B107","doi-asserted-by":"publisher","first-page":"107347","DOI":"10.1016\/j.cmpb.2023.107347","article-title":"An interpretable machine learning approach to estimate the influence of inflammation biomarkers on cardiovascular risk assessment","volume":"230","author":"Roseiro","year":"2023","journal-title":"Comput Methods Programs Biomed"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.semarthrit.2013.05.003","article-title":"High predictive value of the systemic lupus international collaborating clinics\/American college of rheumatology damage index for survival in systemic lupus erythematosus","volume":"29","author":"Nived","year":"2002","journal-title":"J Rheumatol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/annrheumdis-2013-204024","article-title":"Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis","volume":"74","author":"Arts","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B110","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B111","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/2047487315579291","article-title":"An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of Anti-HIV drugs (D:A:D) study","volume":"23","author":"Friis-Moller","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"100552","DOI":"10.1016\/j.eclinm.2020.100552","article-title":"Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets","volume":"27","author":"Matsushita","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B113","doi-asserted-by":"publisher","first-page":"152468","DOI":"10.1016\/j.semarthrit.2024.152468","article-title":"Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus","volume":"67","author":"Choi","year":"2024","journal-title":"Semin Arthritis Rheum"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1601800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:42:26Z","timestamp":1769496146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1601800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":113,"alternative-id":["10.3389\/fcvm.2026.1601800"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1601800","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1601800"}}